Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS) by independent radiologic review committee (IRRC), ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6, testing ivonescimab in combination with ...

Researchers with City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U ...

Citi says the China National Medical Products Administration has just approved ivonescimab in first-line metastatic non-small cell lung cancer ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

Summit Therapeutics (SMMT) noted that Akeso (AKESF) announced ivonescimab was approved by the Chinese Health Authorities for a second ...

A rare cell type in the lungs is essential to survival from the COVID-19 virus, a new study shows.

"We built our platform to systematically address transcription factors, a target class long considered out of reach for small-molecule therapeutics," said Alex Federation, PhD, CEO and Co-Founder of ...

Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...